Literature DB >> 7798291

Revisiting the debate: the use of new agents in previously untreated patients with small cell lung cancer; quality versus duration of survival.

M Markman.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 7798291     DOI： 10.1007/bf01194264

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN： 0171-5216            Impact factor:   4.553


× No keyword cloud information.
  9 in total

1.  Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients.

Authors:  S C Grant; R J Gralla; M G Kris; J Orazem; E A Kitsis
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

2.  Phase II study of 1,2,4-triglycidylurazol (TGU) in previously untreated and treated patients with small cell lung cancer.

Authors:  B Lund; F Hansen; M Hansen; H H Hansen
Journal:  Eur J Cancer Clin Oncol       Date:  1987-07

3.  Testing new drugs in untreated small cell lung cancer may prejudice the results of standard treatment: a phase II study of oral idarubicin in extensive disease.

Authors:  M H Cullen; S R Smith; G F Benfield; C M Woodroffe
Journal:  Cancer Treat Rep       Date:  1987-12

4.  Identification of new drugs in small cell lung cancer: phase II agents first?

Authors:  J Aisner
Journal:  Cancer Treat Rep       Date:  1987-12

5.  Teniposide (VM-26), an overlooked highly active agent in small-cell lung cancer. Results of a phase II trial in untreated patients.

Authors:  E Bork; M Hansen; P Dombernowsky; S W Hansen; A G Pedersen; H H Hansen
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

6.  Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study.

Authors:  M Blackstein; E A Eisenhauer; R Wierzbicki; S Yoshida
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

7.  Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer.

Authors:  W K Evans; E A Eisenhauer; Y Cormier; J Ayoub; R Wierzbicki; F Laberge; F A Shepherd
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

8.  Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study.

Authors:  D S Ettinger; D M Finkelstein; M D Abeloff; R T Skeel; P B Stott; M S Frontiera; P D Bonomi
Journal:  J Natl Cancer Inst       Date:  1992-07-15       Impact factor: 13.506

9.  Phase II trial of edatrexate in small cell lung cancer.

Authors:  M Wiesenfeld; J R Jett; J Q Su; T A Braich; C G Kardinal; J A Mailliard; M H Veeder; R F Morton; J C Michalak
Journal:  Cancer       Date:  1994-02-15       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.